Neoadjuvant therapy was initially investigated in inoperable, locally advanced BC, but has been integrated into the standard of care, particularly in HER-2+ early-stage BC, for 2 cm N0 (according to the TMN classification) or all N+ BC subtypes, and TNBC (87). The gene discussed is ERBB2; the disease is breast cancer.